Jerry Bagel, MD, MS

Experts in dermatology review how JAK inhibitors will impact dermatology care across the board.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, consider how new advances in oral medication will impact physicians’ and patients’ decision-making when it comes to treatment of alopecia areata, vitiligo, and atopic dermatitis.

Dermatology experts discuss clinical specifics of JAK [Janus kinase] inhibitors and their impact on the treatment of patients with vitiligo and alopecia areata.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, discuss the use of topical JAK inhibitors in alopecia areata, vitiligo, and atopic dermatitis.

Brett King, MD, PhD, shares insight on the dosage efficacy of oral JAK inhibitors abrocitinib and upadacitinib in atopic dermatitis.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, explore how severity of disease factors into treatment selection regarding the use of JAK inhibitors.

Drs Jerry Bagel and Brett King discuss safety considerations and the clinical impact of how boxed warnings for JAK inhibitors highlighting how they affect physician decision-making.

Experts in dermatology review currently available JAK inhibitors for use in patients with dermatological conditions and highlight their differences.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, provide an overview of JAK inhibitors and their mechanisms of action in dermatology care.

Experts in plaque psoriasis discuss the future for the management of plaque psoriasis.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss how clinical trials play an important role in the management of plaque psoriasis.

Dr Jerry Bagel and physician assistant Alexa Hetzel comment on the impact of COVID-19 pandemic on patients with plaque psoriasis.

Experts in plaque psoriasis discuss the impact of access to medication for plaque psoriasis and how biosimilars might impact the treatment of plaque psoriasis.

Jerry Bagel, MD, MS, discusses the relationship between a physician and physician assistant treating plaque psoriasis.

Experts in plaque psoriasis discuss how patients are referred to them for treatment.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, touch on unmet needs that remain in the treatment of plaque psoriasis.

Dr Jerry Bagel and physician assistant Alexa Hetzel comment on other agents available for the treatment of plaque psoriasis.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss the safety and efficacy of deucravacitinib in patients with plaque psoriasis.

Panelists talk about when they might consider switching biologics for patients with plaque psoriasis.

Experts in plaque psoriasis discuss how to select a biologic based on patient factors and comorbidities.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss their experiences with biologics used to treat plaque psoriasis.

Jerry Bagel, MD, MS, discusses the mechanism of action of biologics used in plaque psoriasis.

Dr. Jerry Bagel and physician assistant, Alexa Hetzel, comment on the burden of plaque psoriasis and what options are available for the treatment of plaque psoriasis.

Jerry Bagel, M.D., M.S. and Alexa Hetzel, M.S., PA-C discuss an overview of plaque psoriasis and how plaque psoriasis impacts quality of life.

Dr Jerry Bagel looks to the future of moderate-to-severe plaque psoriasis management.

Jerry Bagel, MD, MS, explains clinical trial data on the investigational anti-IL17A/F monoclonal antibody bimekizumab.

An overview of the novel selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for the management of plaque psoriasis.

Dr Jerry Bagel describes the unmet needs of plaque psoriasis management.

An expert dermatologist details the effect of the COVID-19 pandemic and other comorbidities on treatment selection for plaque psoriasis.

Jerry Bagel, MD, MS, discuss new targets, treatment goals, and utilizing shared decision making when treating patients with plaque psoriasis.